Brokerages forecast that Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) will announce earnings per share of ($0.71) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Diffusion Pharmaceuticals’ earnings. Diffusion Pharmaceuticals reported earnings per share of ($0.75) in the same quarter last year, which would indicate a positive year-over-year growth rate of 5.3%. The company is scheduled to report its next earnings report on Wednesday, November 13th.
On average, analysts expect that Diffusion Pharmaceuticals will report full-year earnings of ($2.89) per share for the current fiscal year. For the next fiscal year, analysts forecast that the company will report earnings of ($2.09) per share. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that cover Diffusion Pharmaceuticals.
Diffusion Pharmaceuticals (NASDAQ:DFFN) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.63) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.06.
Hedge funds have recently modified their holdings of the stock. Acadian Asset Management LLC bought a new position in Diffusion Pharmaceuticals in the 2nd quarter worth approximately $48,000. Wells Fargo & Company MN bought a new position in Diffusion Pharmaceuticals in the 2nd quarter worth approximately $427,000. Finally, Anson Funds Management LP bought a new position in Diffusion Pharmaceuticals in the 2nd quarter worth approximately $933,000. 24.35% of the stock is owned by institutional investors and hedge funds.
DFFN stock traded up $0.01 on Monday, reaching $1.80. The company’s stock had a trading volume of 7,900 shares, compared to its average volume of 197,061. Diffusion Pharmaceuticals has a 52 week low of $1.79 and a 52 week high of $11.00. The company has a market capitalization of $8.87 million, a P/E ratio of -0.30 and a beta of 0.06. The firm has a fifty day moving average of $2.00 and a two-hundred day moving average of $2.90. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.02 and a quick ratio of 9.02.
Diffusion Pharmaceuticals Company Profile
Diffusion Pharmaceuticals Inc, a clinical stage biotechnology company, develops treatments for life-threatening medical conditions. Its lead product candidate is transcrocetinate sodium, which is in Phase III trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of pancreatic cancer and metastatic brain cancer; and Phase II trial for the treatment of acute stroke.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.